Trial Profile
A Pilot, Open-Label, Proof-of-Concept Study of the Use of [18F]Fluciclatide PET/CT Imaging in the Evaluation of Anti-Angiogenic Therapy in Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 01 Feb 2017
Price :
$35
*
At a glance
- Drugs Fluciclatide F-18 (Primary)
- Indications Solid tumours
- Focus Diagnostic use; Proof of concept
- 01 May 2014 New trial record